Characteristic features of primary testicular lymphoma and survival trends: a multicenter clinical study

Figures & data

Table 1. Clinical characteristics.

Characteristics	No. of subjects	%
Age
≥60	34	69.39
<60	15	30.61
Laterality
Left	25	51.02
Right	21	42.86
Bilateral	3	6.12
Serum LDH
Normal	30	61.22
Elevated	19	38.78
Pathology classification
GCB	19	38.78
Non-GCB	30	61.22
Stage
I	29	59.18
II	5	10.21
III	6	12.24
IV	9	18.37
IPI score
0–1	27	55.10
2	7	14.29
3	10	20.41
4–5	5	10.20
Ki-67
≥90	20	40.82
<90 and ≥80	12	24.49
<80	17	34.69
ITH
Yes	24	48.98
No	25	51.02
CNS
Involved	3	6.12
Uninvolved	46	93.88

GCB: germinal center B-cell; LDH: lactate dehydrogenase; ITH: intrathecal injection; CNS: central nervous system.

Table 2. Treatment.

Treatment regimen	N (%)
Localized treatment
Orchiectomy alone	6 (12.24)
Systemic treatment
Chemotherapy only	2 (4.08)
Surgery + chemotherapy	29 (59.18)
Surgery + chemotherapy + RT	11 (22.45)
Conservative treatment	1 (2.04)

Table 3. Chemotherapy regimen.

Chemotherapy regimen	N
R-hyper CVAD/MA	4
R-CHOP	23
R-CHOP + higher doses MTX	8
CHOP	6
Rituximab alone	1

R: rituximab; C: cyclophosphamide; H/A: doxorubicin; O/V: vincristine; P: prednisolone; MTX/M: methotrexate; A: cytarabine.

Figure 1. OS of patients with primary testicular lymphoma. Kaplan-Meier survival curves by stage, Ki-67, risk-stratification, age, laterality, LDH and type.

Figure 2. PFS of patients with primary testicular lymphoma. Kaplan-Meier survival curves by stage, Ki-67, risk-stratification, age, laterality, LDH and type.

Figure 3. OS and PFS of patients with primary testicular lymphoma. Kaplan-Meier survival curves by different therapy regimens.